How will they decide? How did they decide last time?

Quote




footprints

loe gone
over 40 gone
female or considered a minority you will be safe
live outside your territory gone
recently hired or promoted you will be safe
good luck
 






Anonymous said:
footprints

loe gone
over 40 gone
female or considered a minority you will be safe
live outside your territory gone
recently hired or promoted you will be safe
good luck
Click to expand...

Agree with most points except- living in territory. Last time they moved most reps around to different territories, and most had really long commutes, none of it made any business sense.
Also no one is safe! They will lay you off if you are new, old, young, sick, dying, out on sick leave--- they dont care and everyone is a target. I will say if your DM loves/is going to bed with you--- you will be safe!
 



This decision has already been made. They can't do this tear the company down and build it back up in a month. As Lonnel said they didn't use a consultant this time because they (McKinsey) figured it out last time. So it really wasn't a lie.
 



Most of hospital sales force gone. Most of primary care gone. One of the marketing vps, either DT or TK is gone. Whoever is closest to LC will stay. SS may be gone as LC really cannot justify the extra layer with no drugs to manage. SS is probably cursing himself for coming here.

Half the RDs gone. Half of managed care gone.

Go ahead, tell me why I'm wrong.
 



Anonymous said:
Most of hospital sales force gone. Most of primary care gone. One of the marketing vps, either DT or TK is gone. Whoever is closest to LC will stay. SS may be gone as LC really cannot justify the extra layer with no drugs to manage. SS is probably cursing himself for coming here.

Half the RDs gone. Half of managed care gone.

Go ahead, tell me why I'm wrong.
Click to expand...

absolutely right.

As far as who stays over marketing, DT or TK, it's got to be DT. DT learning primary care is much easier than TK learning oncology.

Who cares about SS.
 









Anonymous said:
You are completely off base with primary care. They will for the most part be untouched this time around. They bring the revenue
Click to expand...

No primary care will be hit because they will have pfizer sample drop that joke of drug Aricept 23. And some of the other drugs can be sold by JNJ, why do you think that the Pfzer reps have carried the 23 for a year?
 



Anonymous said:
Most of hospital sales force gone. Most of primary care gone. One of the marketing vps, either DT or TK is gone. Whoever is closest to LC will stay. SS may be gone as LC really cannot justify the extra layer with no drugs to manage. SS is probably cursing himself for coming here.

Half the RDs gone. Half of managed care gone.

Go ahead, tell me why I'm wrong.
Click to expand...

There is no longer "Clinic" and "Hospital" reps. Everyone is classified as Critical Care Oncology. When they start cutting territories, whether you are a longtime clinic or hospital rep under SFE will have NO bearing. The criteria will be but not limited to:

1. Halaven Sales
2. Territory viability (and not % to goal. Think overall product revenue)
3. Direct labor cost (salary and benefits)
4. Current Standing (non LOE and past reviews)

Don't kind yourself if you think the simple solution is to eliminate a certain sales force. You will see roughly 20-30% reduction on the oncology side, and is will not be "SFE Hospital Reps". EVERYONE is fair game right now. THAT IS WHY YOU ARE WRONG.
 



Anonymous said:
absolutely right.

As far as who stays over marketing, DT or TK, it's got to be DT. DT learning primary care is much easier than TK learning oncology.

Who cares about SS.
Click to expand...

Agree that DT will stay and TK-SS will likely be gone. What about all the other clowns in marketing a level or two down from there? Such as, Young (Aciphex), Shull (Aricept), Asch (Halaven), Hoosier (Fragmin), etc.? The all gone too?
 



Anonymous said:
There is no longer "Clinic" and "Hospital" reps. Everyone is classified as Critical Care Oncology. When they start cutting territories, whether you are a longtime clinic or hospital rep under SFE will have NO bearing. The criteria will be but not limited to:

1. Halaven Sales
2. Territory viability (and not % to goal. Think overall product revenue)
3. Direct labor cost (salary and benefits)
4. Current Standing (non LOE and past reviews)

Don't kind yourself if you think the simple solution is to eliminate a certain sales force. You will see roughly 20-30% reduction on the oncology side, and is will not be "SFE Hospital Reps". EVERYONE is fair game right now. THAT IS WHY YOU ARE WRONG.
Click to expand...

Agree with everything except the cuts will be around 50%, not 20-30%. Simple math, the revenue is projected to be half so half the field must be let go. The people who are left will have a 3rd realignment in under 2 years.
 



Anonymous said:
You are completely off base with primary care. They will for the most part be untouched this time around. They bring the revenue
Click to expand...

With dismal 23 sales and Aciphex share being eaten away at an ever increasing monthly rate (and no ER in sight), the $$$ are just not there to retain the PC sales force. Most likely, 50% of PC's will be gone by March 31st.
 






Anonymous said:
With dismal 23 sales and Aciphex share being eaten away at an ever increasing monthly rate (and no ER in sight), the $$$ are just not there to retain the PC sales force. Most likely, 50% of PC's will be gone by March 31st.
Click to expand...

TK will be out for the reasons mentioned in the other posts, and the new structure in marketing will be a few directors keeping the brands alive and kicking until new products come. Aricept and Aciphex will be well over a billion in sales which will pay the bills along with Aloxi while DT creates the future.

AM, DC, SR, PS, LP, OB, DA, JH, DJ, CS, AY, SB, will all be on the chopping block or on the list for the reorg. Some up, some over and some out. Friends of LC may continue to survive.
 



Anonymous said:
TK will be out for the reasons mentioned in the other posts, and the new structure in marketing will be a few directors keeping the brands alive and kicking until new products come. Aricept and Aciphex will be well over a billion in sales which will pay the bills along with Aloxi while DT creates the future.

AM, DC, SR, PS, LP, OB, DA, JH, DJ, CS, AY, SB, will all be on the chopping block or on the list for the reorg. Some up, some over and some out. Friends of LC may continue to survive.
Click to expand...

You said Aricept and Aciphex will be well over billion. Yeah right. You should be part of the home office forecasting group since you're as clueless as them.
 



Anonymous said:
There is no longer "Clinic" and "Hospital" reps. Everyone is classified as Critical Care Oncology. When they start cutting territories, whether you are a longtime clinic or hospital rep under SFE will have NO bearing. The criteria will be but not limited to:

1. Halaven Sales
2. Territory viability (and not % to goal. Think overall product revenue)
3. Direct labor cost (salary and benefits)
4. Current Standing (non LOE and past reviews)

Don't kind yourself if you think the simple solution is to eliminate a certain sales force. You will see roughly 20-30% reduction on the oncology side, and is will not be "SFE Hospital Reps". EVERYONE is fair game right now. THAT IS WHY YOU ARE WRONG.
Click to expand...

You are correct. I have this confirmed. Believe otherwise and you are in denial. Clinic rep with no Halaven is in trouble especially if high salary. Same for hospital rep.
 



Anonymous said:
There is no longer "Clinic" and "Hospital" reps. Everyone is classified as Critical Care Oncology. When they start cutting territories, whether you are a longtime clinic or hospital rep under SFE will have NO bearing. The criteria will be but not limited to:

1. Halaven Sales
2. Territory viability (and not % to goal. Think overall product revenue)
3. Direct labor cost (salary and benefits)
4. Current Standing (non LOE and past reviews)

Don't kind yourself if you think the simple solution is to eliminate a certain sales force. You will see roughly 20-30% reduction on the oncology side, and is will not be "SFE Hospital Reps". EVERYONE is fair game right now. THAT IS WHY YOU ARE WRONG.
Click to expand...

Halaven is Eisai Oncology!
Aloxi is flat, late stage.
 







Write your reply...
Top Bottom
Back
Quote